Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Net Margin (2016 - 2025)

Coherus Oncology's Net Margin history spans 12 years, with the latest figure at 68.28% for Q4 2025.

  • For Q4 2025, Net Margin rose 12780.0% year-over-year to 68.28%; the TTM value through Dec 2025 reached 832.66%, up 56496.0%, while the annual FY2025 figure was 832.66%, 9160.0% down from the prior year.
  • Net Margin for Q4 2025 was 68.28% at Coherus Oncology, down from 77.66% in the prior quarter.
  • Across five years, Net Margin topped out at 7405.16% in Q1 2024 and bottomed at 233.47% in Q1 2023.
  • The 5-year median for Net Margin is 60.9% (2021), against an average of 490.4%.
  • The largest annual shift saw Net Margin skyrocketed 763863bps in 2024 before it crashed -752584bps in 2025.
  • A 5-year view of Net Margin shows it stood at 62.28% in 2021, then plummeted by -108bps to 129.81% in 2022, then skyrocketed by 33bps to 87.03% in 2023, then surged by 32bps to 59.52% in 2024, then skyrocketed by 215bps to 68.28% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Net Margin are 68.28% (Q4 2025), 77.66% (Q3 2025), and 3341.42% (Q2 2025).